A new chapter in dementia care begins at Bruyère Health
04/20/2026
At Bruyère Health, we are marking an important
milestone in the evolution of dementia care, one that signals both progress and
possibility.
This week, a patient at our Memory Clinic
became the first in the region to begin treatment with lecanemab, the first
disease-modifying therapy for Alzheimer’s disease approved for use in Canada.
Treatments like these are shifting
the conversation from disease management to treatment for some patients with early-stage
Alzheimer’s. For individuals and families navigating the realities of this
condition, this moment represents an important step forward and is providing
hope.
Learn more about lecanemab and the Bruyère Health Dementia strategy.
Reaching this milestone
required years of research and extraordinary coordination and commitment. Our clinical teams
worked in close collaboration with partners across the health care system to
ensure the safe and timely introduction of this therapy. Their efforts reflect
the strength of an integrated, learning health system, one that is capable of
translating innovation into real-world care.
At Bruyère Health, our focus on dementia is
both intentional and urgent. As an academic health sciences centre specializing
in aging, rehabilitation, and complex care, we see firsthand the impact
dementia has on individuals, families, and the broader health system. That is
why we are committed to reimagining care through the lens of those we care for.
The introduction of
lecanemab is the first initiative under the Leading Edge Specialized Care
pillar of our corporate Dementia Strategy. It reflects our ambition to bring
the most advanced treatments, research, and models of care together.
This milestone is not an
endpoint. It is the beginning of a new chapter where discovery, collaboration,
and purpose come together to improve quality of life for those living with
dementia and those who care for them.